StreetAlpha.app
Home › Stocks › ALT

Altimmune, Inc. (ALT)

Healthcare
$1.53
▼ −1.92%
LAST CLOSE · NOV 17

Altimmune develops pemvidutide, an investigational peptide treatment for serious liver diseases such as MASH. It last closed at $1.53 on Nov 17, down 1.92% on the day. The average 12-month price target from 2 analysts is $12.50 (+717.0% from the last close), with a high of $14.00 and a low of $11.00.

AI Auto Pilots
Is ALT in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$104.4M
EPS (diluted)
−$0.71
Free cash flow
−$102.5M
Valuation
Market cap
$297.7M
194.6M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$28.9M
At Sep 30
Debt
$35.0M
At Sep 30
Shareholder equity
$443.6M
Shares outstanding
194.6M
At Nov 6
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $4.4M$4.4MFY2021FY2022: −$68K−$68KFY2022FY2023: $426K$426KFY2023FY2024: $20K$20KFY2024FY2025: $41K$41KFY2025

From ALT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Last report
Nov 12
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
2 Buy
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Buy
2firms
2 Buy0 Hold0 Sell
Only 2 firms rated ALT in the past 90 days, not enough for a consensus
Average 12-month target
$12.50
▲ 717.0% upside

Based on 2 analysts who set a price target on ALT in the past 90 days. The average target is $12.50, with a high of $14.00 and a low of $11.00, compared with the last close of $1.53.

$1$5$10$15PAST 19 TRADING DAYS12-MONTH TARGETSHIGH $14AVG $12.50LOW $11Jun 9LAST CLOSE+12 MO$1$5$10$15PAST 19 DAYSTARGETSHIGH $14AVG $12.50LOW $11Jun 9LAST CLOSE+12 MO
Highest target$14.00
Average target$12.50
Lowest target$11.00
Latest rating changes
Evercore ISI GroupTarget lowered
Nov 16Buy$17 → $14
B. Riley SecuritiesReiterated
Nov 13Buy$11
Evercore ISI GroupMaintained
Sep 23Buy$17
Leerink PartnersInitiated
Jun 22Buy$10
HC Wainwright & Co.Maintained
May 18Buy$20
DateFirmActionRatingPrice target
Nov 16Evercore ISI GroupTarget loweredBuy$17 → $14
Nov 13B. Riley SecuritiesReiteratedBuy$11
Sep 23Evercore ISI GroupMaintainedBuy$17
Jun 22Leerink PartnersInitiatedBuy$10
May 18HC Wainwright & Co.MaintainedBuy$20
Loading…

Technical Analysis

ALT · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 29% below its 20 day and 64% below its 50 day average. It is 102% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 24), oversold. The nearest support is the Pivot S1 at $1.51, and the nearest resistance the Pivot R1 at $1.55.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 8.9%/day
Key levels
$6.4452 week high+320.9%
$3.09200 day average+102.0%
$2.77100 day average+81.0%
$2.5150 day average+64.1%
$2.18Swing high (Oct 29)+42.5%
$1.9720 day average+28.8%
$1.55Pivot R1+1.3%
$1.53Pivot+0.0%
$1.53Last close
$1.51Pivot S1−1.3%
$1.5052 week low−2.0%
Indicators
RSI (14)23.93Oversold below 30Oversold
MACD-0.24Below its signal lineBearish
Stochastic7.4Near the bottom of its rangeOversold
ADX (14)43.2Strong downtrend
Williams %R-95.8Oversold below −80, overbought above −20Oversold
CCI (20)-196.2Oversold below −100, overbought above 100Oversold
Rate of change−25.0%Change over 10 sessionsBearish
ATR (14)$0.14Typical daily range, 8.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ALT

What happened before

See how ALT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow ALT usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How ALT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in ALT in the last 90 days.

Loading…

See today’s whale options flow across the market →

ALT Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼92 buying vs 108 selling
  • ▼Held by funds -4.6 pts
  • ▼Funds holding -18
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding192210−8.6%
In funds' top 1000–
Held by funds73.3%77.9%−4.6 pts
New / increased29 / 6358 / 87−36.6%
Reduced / sold out62 / 4633 / 18+111.8%
Put/call ratio0.070.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ALT institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ALT is in one of them and how their past ALT trades turned out.

ALT in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ALT in an article yet. Here's the latest on the wider market.

About Altimmune

Altimmune is a biopharmaceutical company based in Gaithersburg, Maryland, that develops treatments for serious liver diseases. Its lead product candidate, pemvidutide, is an investigational peptide designed to act on both glucagon and GLP-1 receptors. The company is studying pemvidutide for steatohepatitis, a form of fatty liver disease, as well as for alcohol use disorder and liver disease caused by alcohol. Its target patients are people living with these conditions, and the drug is not yet approved for sale.

Headquarters
Morristown, NJ